BioMarin
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| rareDisease | ×1.32 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 6 disclosed transactions, BioMarin concentrates its licensing activity in RareDisease, Other. BioMarin pays a 1.32x premium over market median, with the strongest premiums in RareDisease (1.32x). Their most common deal structure is Acquisition, with an average disclosed value of $2.6B. Most recent activity: 2026.
Premium by therapeutic area
How BioMarin pays relative to peer medians in each TA
Pipeline coverage & gaps
BioMarin has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 6 | $2.5B | $2.6B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | ALE1 | Alesta Therapeutics | hypophosphatasia | unknown | $275M | $490M |
| 2026 | ALE1 | Alesta Therapeutics | hypophosphatasia | phase_1 | $275M | $490M |
| 2025 | Amicus Therapeutics (full company acquisition; includes Galafold and pipeline) | Amicus Therapeutics | Fabry disease | approved | $4.8B | $4.8B |
| 2025 | Fabry programs | Amicus | Fabry disease | unknown | $4.8B | $4.8B |
| 2025 | Inozyme Pharma (INZ-701, ENPP1 deficiency) | Inozyme Pharma | rare diseases | phase_3 | $270M | $270M |
| 2025 | Galafold (migalastat) + pipeline | Amicus Therapeutics | Fabry Disease | approved | $4.8B | $4.8B |
How this is computed
For each BioMarin deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.319, clamped to [0.7, 1.5].